Epcoritamab Rituximab Lenalidomide R/R Follicular Lymphoma Treatment
- Here's a breakdown of the key findings from the Phase 3 EPCORE FL-1 trial (NCT05409066):
- * Notable Improvement in Progression-Free Survival (PFS): Epcoritamab combined with R2 reduced the risk of disease progression or death by 79% compared to R2 alone (HR 0.21,95% CI...
- Essentially, the trial demonstrates a substantial benefit in PFS for patients treated with epcoritamab plus R2 compared to R2 alone, with a manageable safety profile.
Here’s a breakdown of the key findings from the Phase 3 EPCORE FL-1 trial (NCT05409066):
* Notable Improvement in Progression-Free Survival (PFS): Epcoritamab combined with R2 reduced the risk of disease progression or death by 79% compared to R2 alone (HR 0.21,95% CI 0.13-0.33,P* < .0001).
* Unreached Median PFS: Patients receiving epcoritamab + R2 had a median PFS that was *not reached, while those on R2 alone had a median PFS of 11.2 months.
* Treatment Duration: The regimen was given in 28-day cycles for a maximum of 12 cycles, or until disease progression or unacceptable toxicity occurred.
* Safety Profile: The safety profile of the combination was consistent with what’s known about the individual drugs.
* Common Adverse Events: These included rash, upper respiratory tract infections, fatigue, injection site reactions, constipation, diarrhea, cytokine release syndrome (CRS), pneumonia, COVID-19, and fever.
* Common Grade 3-4 Lab Abnormalities (affecting ≥10% of patients): Decreased neutrophil count and lymphocyte count.
Essentially, the trial demonstrates a substantial benefit in PFS for patients treated with epcoritamab plus R2 compared to R2 alone, with a manageable safety profile.